Abstract: Compositions comprising tRNA synthetase polypeptides useful for regulating angiogenesis, as well as nucleic acids encoding such tRNA synthetase polypeptides are described. Methods of making and using such compositions are also disclosed.

Abstract: An air distribution arrangement is adapted to be arranged in a cabinet for housing rack-mounted equipment that generates heat in use. The arrangement can be part of the cabinet when constructed or it can be an add-on feature. The arrangement includes plenum structure comprising side walls and a top wall that cooperates with the front door of the cabinet and the faces of the rack-mounted equipment to define a plenum. An air box in the cabinet draws ambient air from adjacent the floor into the plenum at a rate of at least 850 cfm. The ambient air is cooler than the air in the cabinet. The faces of the rack-mounted equipment have openings for receiving the ambient air to cool the interiors thereof. After cooling the rack-mounted equipment the air can be exhausted back to the ambient. The side walls and the top wall of the arrangement are adjustable to permit adjustment of the depth of the plenum. Pressure in the plenum can be relieved by slots in the plenum structure.

Abstract: Technology is provided for treating recirculating water in a system to control algae in, for example, a cooling water, an evaporative condenser, a heat exchanger, or a decorative fountain. A solid composition comprising terbuthylazine dispersed in polyethylene glycol is contacted with recirculating water. The polyethylene glycol slowly dissolves, and the terbuthylazine is delivered into the water. The composition is preferably prepared by dispersing the terbuthylazine in molten polyethylene glycol followed by molding and solidifying. A preferred polyethylene glycol has an average molecular weight of about 8,000. The system can accomplish addition of terbuthylazine to recirculated water without the need for a dosing pump and without exposure of operating personnel to terbuthylazine.

Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

Abstract: Angiogenesis inhibitors and methods of use thereof are disclosed. The inhibitors are substantially pure oligopeptides consisting essentially of 7–20 amino acid residues and comprising a proline-rich sequence of five amino acid residues PPXPP, SEQ ID NO: 1, wherein X is an amino acid residue selected from the group consisting of alanine, glycine, serine, threonine, valine, leucine and methionine. In a preferred embodiment, the proline-rich polypeptide is covalently bound to a transport molecule such as a Tat-derived transport polypeptide.

Abstract: Protein, or parts of proteins, may be rendered non-immunogenic, or less immunogenic, to a given species by identifying in their amino acid sequences one or more potential epitopes for T-cells of the given species and modifying the amino acid sequence to eliminate at least one of the T-cell epitopes. This eliminates or reduces the immunogenicity of the protein when exposed to the immune system of the given species. Monoclonal antibodies and other immunoglobulin-like molecules can particularly benefit from being de-immunised in this way: for example, mouse-derived immunoglobulins can be de-immunised for human therapeutic use.

Abstract: An illumination apparatus is provided that can achieve light distribution towards the front, and light illumination in a direction other than the front direction, without using a light source other than the light source for frontward illumination. The illumination apparatus includes a light emitting diode located at the front side of the illumination apparatus, corresponding to one end, a side transmission unit having a surface exposed at a gap in the casing, located rearward of the light emitting diode to transmit light from the side, and a light path modification unit, located rearward of the light emitting diode to modify the direction of light output from the light emitting diode towards the side transmission unit.

Abstract: Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-?v?3 are inhibited by an inhibitor compound of formula (I): wherein G1 and G2 are each independently NH—C(O)—O—R1, —NH—C(O)—O—(CH2)v—(C6H4)—X3, —NH—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—NH—(CH2)v—(C6H4)—X3, —O—C(O)—O—(CH2)v—(C6H4)—X3, or NH—C(O)—CH2—(C6H4)—X3; Y1 and Y2 are each independently OH, C1–C4 alkyl, C1–C4 hydroxyalkyl, C1–C4 alkoxy, phenyl, benzyl, or NH2; R1 is C1–C4 alkyl; X1 and X2 are each independently halo or C1–C4 alkoxy; X3 is halo, nitro, C1–C4 alkyl, C1–C4 alkoxy, or C1–C4 perfluoroalkyl; Z is —C?C—, —C6H4—, cis-CH?CH—, trans CH?CH—, cis-CH2—CH?CH—CH2—, trans —CH2—CH?CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1, 3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each independently an integer having a value of 0 or 1; t is an integer having a value of 0 or 1; and p, r, and v are each independently an integer having a value of 1 or 2; with provisos that when A

Abstract: Hematocrit in a blood sample is visualized by separating blood plasma from red blood cells in the blood sample on an absorbent substrate provided with a blood plasma soluble dye. Methods and devices to achieve the visualization are described.

Abstract: Gurmarin containing compositions are useful for the treatment of diabetes. Glucose metabolism in a human patient is regulated by gurmarin-containing dosage forms that contain optionally a non-metabolizable polysaccharide such as the exudate of Sterculia urens.

Abstract: The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.

Abstract: An electrodialysis cell (40) suitable for removal of paint solubilizer from electrocoat paint ultrafilter permeate includes a tubular, non-conductive housing (42), a substantially cylindrical, hollow object electrode (48) in the housing, a substantially cylindrical counter electrode (52) situated within the hollow object electrode, and a tubular ion exchange membrane (50) around the counter electrode but spaced from the counter electrode as well as the object electrode. The counter electrode and the tubular membrane together define an annular electrolyte passageway while the object electrode and the tubular membrane together define an annular ultrafilter permeate passageway. The object electrode-to-counter electrode area ratio is at least about 6.

Abstract: A container (10) has a lid (12) for rotation mounting thereon. A tamper evident mechanism is located for operation between the container and lid. The mechanism includes at least one projection (42) on the container and at least one corresponding flange (44) on the lid. Each flange and projection pair is arranged such that, when the lid is rotation mounted on the container, the flange moves relatively past the projection to a position such that removal of the lid by counter rotation may only occur by deforming or breaking of the flange and/or projection.